The research progress of SARS-CoV-2 main protease inhibitors from 2020 to 2022

The novel coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread worldwide. The main protease (M(pro)) of SARS-CoV-2 plays a central role in viral replication and transcription and represents an attractive drug target for fighting COVID-...

Descripción completa

Detalles Bibliográficos
Autores principales: Pang, Xiaojing, Xu, Wei, Liu, Yang, Li, Hua, Chen, Lixia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Masson SAS. 2023
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10201905/
https://www.ncbi.nlm.nih.gov/pubmed/37244162
http://dx.doi.org/10.1016/j.ejmech.2023.115491
Descripción
Sumario:The novel coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread worldwide. The main protease (M(pro)) of SARS-CoV-2 plays a central role in viral replication and transcription and represents an attractive drug target for fighting COVID-19. Many SARS-CoV-2 M(pro) inhibitors have been reported, including covalent and noncovalent inhibitors. The SARS-CoV-2 M(pro) inhibitor PF-07321332 (Nirmatrelvir) designed by Pfizer has been put on the market. This paper briefly introduces the structural characteristics of SARS-CoV-2 M(pro) and summarizes the research progress of SARS-CoV-2 M(pro) inhibitors from the aspects of drug repurposing and drug design. These information will provide a basis for the drug development of treating the infection of SARS-CoV-2 and even other coronaviruses in the future.

Ejemplares similares